Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The week of March 15, or even sooner

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Feb 11, 2021 6:03pm

132 Views

Post# 32547593

RE:RE:The week of March 15, or even sooner

Marky1, it is on Dan's action list. IMHO, now it is the best time to initiate the process.$20M from the China deal is not sufficent to complete PIII. ATE must get funding either through more partner deals, or, through institutional investors. And, obviously, Nasdaq is the best place to attract institutional investor attention. If Dan has to do it sooner than later, now is the best time to do so.